FRM
BBOT icon

Fox Run Management’s BridgeBio Oncology BBOT Stock Holding History

Fox Run Management’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$208K Buy
+50,778
New +$395K 0.02% 851

Other funds holding BBOT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Regents of the University of California
Regents of the University of California Oakland, California $6.64B AUM 23.46% 1-Year Est. Return
Laurion Capital Management
Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Aisling Capital Management
Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Fox Run Management's BBOT Position: Q3 2026 in Review

Fox Run Management opened a new position in BridgeBio Oncology (BBOT) in Q3 2026: 50,778 shares worth $208K. The stake represents 0.02% of the portfolio and ranks #851 among its holdings.

44 funds tracked by Wall St. Rank hold BBOT as of Q3 2026.

  • Fox Run Management held 50,778 shares of BridgeBio Oncology worth $208K as of Q3 2026.
  • BridgeBio Oncology was a new Fox Run Management position in Q3 2026.
  • BridgeBio Oncology made up 0.02% of Fox Run Management's portfolio in Q3 2026, its #851 holding.
  • 44 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q3 2026.

Based on Fox Run Management's 13F filing for Q3 2026, filed 12 Nov 2026.